Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Nov 10

PMID 33167582

Citations 25

Authors

Laura Menotti

Elisa Avitabile

Affiliations

Soon will be listed here.

Abstract

Oncolytic viruses are smart therapeutics against cancer due to their potential to replicate and produce the needed therapeutic dose in the tumor, and to their ability to self-exhaust upon tumor clearance. Oncolytic virotherapy strategies based on the herpes simplex virus are reaching their thirties, and a wide variety of approaches has been envisioned and tested in many different models, and on a range of tumor targets. This huge effort has culminated in the primacy of an oncolytic HSV (oHSV) being the first oncolytic virus to be approved by the FDA and EMA for clinical use, for the treatment of advanced melanoma. The path has just been opened; many more cancer types with poor prognosis await effective and innovative therapies, and oHSVs could provide a promising solution, especially as combination therapies and immunovirotherapies. In this review, we analyze the most recent advances in this field, and try to envision the future ahead of oHSVs.

Citing Articles

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review.

Borella F, Carosso M, Chiparo M, Ferraioli D, Bertero L, Gallio N Pathogens. 2025; 14(2).

PMID: 40005517 PMC: 11858389. DOI: 10.3390/pathogens14020140.

The role of herpes simplex virus infection in the etiology of head and neck cancer-a Mendelian randomization study.

Yan M, Xiao L, Gosau M, Smeets R, Feng H, Burg S Front Immunol. 2024; 15:1278327.

PMID: 39161761 PMC: 11331341. DOI: 10.3389/fimmu.2024.1278327.

Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.

Gujar S, Pol J, Kumar V, Lizarralde-Guerrero M, Konda P, Kroemer G Nat Protoc. 2024; 19(9):2540-2570.

PMID: 38769145 DOI: 10.1038/s41596-024-00985-1.

TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1.

Funk C, Uhlig N, Ruzsics Z, Baur F, Peindl M, Nietzer S Mol Ther Oncol. 2024; 32(1):200784.

PMID: 38596296 PMC: 10950833. DOI: 10.1016/j.omton.2024.200784.

Different Infectivity of Swine Enteric Coronaviruses in Cells of Various Species.

Li Z, Chen Y, Li L, Xue M, Feng L Pathogens. 2024; 13(2).

PMID: 38392912 PMC: 10891669. DOI: 10.3390/pathogens13020174.

References

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C . A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 2018; 14(8):e1007209. PMC: 6095629. DOI: 10.1371/journal.ppat.1007209. View

Simpson G, Relph K, Harrington K, Melcher A, Pandha H . Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother. 2016; 5:1-13. PMC: 4996257. DOI: 10.2147/OV.S66083. View

Sasso E, Froechlich G, Cotugno G, DAlise A, Gentile C, Bignone V . Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Sci Rep. 2020; 10(1):4307. PMC: 7062820. DOI: 10.1038/s41598-020-61275-w. View

Menotti L, Leoni V, Gatta V, Petrovic B, Vannini A, Pepe S . oHSV Genome Editing by Means of galK Recombineering. Methods Mol Biol. 2019; 2060:131-151. DOI: 10.1007/978-1-4939-9814-2_7. View

Vannini A, Petrovic B, Gatta V, Leoni V, Pepe S, Menotti L . Rescue, Purification, and Characterization of a Recombinant HSV Expressing a Transgenic Protein. Methods Mol Biol. 2019; 2060:153-168. DOI: 10.1007/978-1-4939-9814-2_8. View

Toda M, Martuza R, Kojima H, Rabkin S . In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998; 160(9):4457-64. View

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

Mackie R, Stewart B, Brown S . Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001; 357(9255):525-6. DOI: 10.1016/S0140-6736(00)04048-4. View

Todo T, Martuza R, Rabkin S, Johnson P . Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001; 98(11):6396-401. PMC: 33479. DOI: 10.1073/pnas.101136398. View

10.

Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y . Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer. Mol Ther Oncolytics. 2020; 17:205-215. PMC: 7178322. DOI: 10.1016/j.omto.2020.03.022. View

11.

Patel D, Foreman P, Nabors L, Riley K, Gillespie G, Markert J . Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev. 2016; 27(2):69-78. PMC: 4932657. DOI: 10.1089/humc.2016.031. View

12.

Guo Z, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B . Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol. 2017; 8:555. PMC: 5430078. DOI: 10.3389/fimmu.2017.00555. View

13.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

14.

Currier M, Eshun F, Sholl A, Chernoguz A, Crawford K, Divanovic S . VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther. 2013; 21(5):1014-23. PMC: 3666636. DOI: 10.1038/mt.2013.39. View

15.

Chiocca E, Rabkin S . Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014; 2(4):295-300. PMC: 4303349. DOI: 10.1158/2326-6066.CIR-14-0015. View

16.

Toda M, Martuza R, Rabkin S . Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000; 2(4):324-9. DOI: 10.1006/mthe.2000.0130. View

17.

Liu X, Xin H, Lyu Y, Ma Z, Peng X, Xiang Y . Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins. Drug Deliv. 2019; 25(1):1950-1962. PMC: 6282442. DOI: 10.1080/10717544.2018.1534895. View

18.

Kuruppu D, Tanabe K . HSV-1 as a novel therapy for breast cancer meningeal metastases. Cancer Gene Ther. 2015; 22(10):506-8. PMC: 4766812. DOI: 10.1038/cgt.2015.43. View

19.

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

20.

Cassady K, Gross M, Roizman B . The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol. 1998; 72(9):7005-11. PMC: 109920. DOI: 10.1128/JVI.72.9.7005-7011.1998. View